Free tool
FAERS Monitor: Eryped
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050207 or its brand name (Eryped, Erythromycin Ethylsuccinate). Reports on generic versions are filed under their own applications.
Reports
609
Serious
361
59% of reports
Hospitalization
149
Death reported
35
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug hypersensitivity72
- vomiting45
- nausea41
- diarrhoea36
- off label use34
- rash24
- dyspnoea23
- hypersensitivity22
- product use in unapproved indication22
- abdominal pain21
- pruritus21
- urticaria17
- drug ineffective16
- malaise16
- anxiety15
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 13 |
| 2005 | 11 |
| 2006 | 8 |
| 2007 | 5 |
| 2008 | 15 |
| 2009 | 13 |
| 2010 | 30 |
| 2011 | 26 |
| 2012 | 17 |
| 2013 | 35 |
| 2014 | 21 |
| 2015 | 17 |
| 2016 | 45 |
| 2017 | 37 |
| 2018 | 46 |
| 2019 | 53 |
| 2020 | 32 |
| 2021 | 30 |
| 2022 | 13 |
| 2023 | 31 |
| 2024 | 45 |
| 2025 | 45 |
| 2026 | 21 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,550 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug hypersensitivitySignal | 72 | 12.9 | 10.3 | 782 |
| hypersensitivitySignal | 22 | 4.1 | 2.7 | 49 |
| urticariaSignal | 17 | 3.5 | 2.2 | 28 |
| vomitingSignal | 45 | 3.3 | 2.5 | 72 |
| abdominal painSignal | 21 | 3.1 | 2.0 | 28 |
| product use in unapproved indicationSignal | 22 | 3.1 | 2.0 | 29 |
| diarrhoea | 36 | 1.9 | 1.4 | 16 |
| rash | 24 | 1.9 | 1.3 | 10 |
| pruritus | 21 | 1.9 | 1.2 | 8 |
| anxiety | 15 | 1.8 | 1.1 | 5 |
| nausea | 41 | 1.8 | 1.3 | 14 |
| dyspnoea | 23 | 1.4 | 0.9 | 2 |
| off label use | 34 | 1.3 | 1.0 | 3 |
| malaise | 16 | 1.3 | 0.8 | 1 |
| drug ineffective | 16 | 0.4 | 0.3 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.